仙乐健康(300791) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥676,865,104.35, representing a year-over-year increase of 16.11%[5] - Net profit attributable to shareholders for the same period was ¥66,253,052.91, up 21.33% compared to the previous year[5] - The net profit after deducting non-recurring gains and losses was ¥65,405,277.67, reflecting a 25.80% increase year-over-year[5] - The company's basic earnings per share for Q3 2022 was ¥0.37, an increase of 23.33% compared to the same period last year[5] - Net profit for the third quarter of 2022 was CNY 176,169,128.33, a decrease of 12.06% compared to CNY 200,383,925.05 in the same period last year[74] - Total revenue from sales of goods and services reached CNY 2,028,245,946.14, up from CNY 1,845,335,283.73 year-on-year, representing an increase of 9.88%[78] - Operating profit for the quarter was CNY 210,154,581.61, down from CNY 237,056,672.55, reflecting a decline of 11.34%[74] - Total comprehensive income for the quarter was CNY 175,033,665.64, down from CNY 187,053,709.00, a decrease of 6.83%[76] - Basic earnings per share were CNY 0.98, down from CNY 1.11 in the same quarter last year, reflecting a decline of 11.71%[76] Assets and Liabilities - Total assets at the end of the reporting period reached ¥4,065,042,753.66, marking a 6.41% increase from the end of the previous year[5] - The company's total liabilities increased to RMB 1,398 million from RMB 1,275 million, representing a rise of approximately 9.6% year-to-date[44] - The company's equity attributable to shareholders reached RMB 2,667 million, up from RMB 2,545 million, indicating an increase of about 4.8%[57] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥344,494,899.47, up 15.59% compared to the previous year[5] - The company reported a net cash inflow from operating activities of CNY 344,494,899.47, compared to CNY 298,028,406.20 in the previous year, an increase of 15.56%[82] - Investment activities resulted in a net cash outflow of CNY 68,894,199.27, an improvement from a net outflow of CNY 414,821,096.01 in the previous year[82] - Net cash flow from financing activities was -$71.81 million, compared to $948.33 million in the previous period[84] - Total cash and cash equivalents at the end of the period amounted to $923.44 million, up from $1.04 billion in the previous period[84] - The initial cash and cash equivalents balance was $708.73 million, leading to a significant increase by the end of the period[84] Shareholder Information - The total number of shareholders at the end of the reporting period was 9,368, with Guangdong Guanghui Investment Co., Ltd. holding 43.16% of shares[14] - The top 10 shareholders include several individuals with significant stakes, such as Chen Qiong with 7.48% and Lin Peiqing with 7.19%[14] - The total number of restricted shares at the beginning of the period was 16,588,800, which were all released during the period, resulting in zero restricted shares at the end[19] Investments and Acquisitions - The company completed the acquisition of 80% equity in BestFormulationsInc. on July 6, 2022, which is part of its fundraising project for issuing A-shares[20] - The company has passed the U.S. antitrust review for the acquisition of BestFormulationsInc.[23] - The company is uncertain if the acquisition will be approved by the shareholders' meeting, as it requires a two-thirds majority vote[23] - The company raised up to RMB 1,350 million through a targeted issuance of A-shares, with the net proceeds allocated for acquiring 80% of BestFormulations Inc. and supplementing working capital[24] Government Support and Subsidies - The company received government subsidies amounting to ¥3,277,129.80 during the reporting period, contributing to its financial performance[8] Research and Development - Research and development expenses amounted to CNY 60,745,994.30, slightly up from CNY 59,244,496.97, indicating a focus on innovation[74] Cost Management - Total operating costs for the third quarter of 2022 were RMB 1,602 million, compared to RMB 1,534 million in the previous year, marking an increase of about 4.4%[67] - Sales expenses decreased to CNY 86,670,799.62 from CNY 105,774,897.86, a reduction of 18.05%, indicating cost control measures[74] Miscellaneous - The company has obtained necessary approvals for overseas investment, including the issuance of the Overseas Investment Certificate by the Guangdong Provincial Department of Commerce[23] - The company has completed the foreign investment project filing procedures with the Guangdong Provincial Development and Reform Commission[23] - The company does not know if there are any related party relationships among the top 10 unrestricted shareholders[17] - The company has not disclosed any related party transactions in the acquisition of BestFormulationsInc.[20] - The company’s board of directors issued the report on October 26, 2022[86] - The company did not undergo an audit for the third quarter report[85]